​

Edwards Lifesciences (EW) Stock Forecast, Price Target & Predictions

OverviewRevenueOwnershipFinancialsChartTranscripts

EW Stock Forecast

Edwards Lifesciences (EW) stock forecast, based on 48 Wall Street analysts, predicts a 12-month average price target of $96.38, with a high of $110.00 and a low of $87.00. This represents a 17.39% increase from the last price of $82.10.

$60 $70 $80 $90 $100 $110 High: $110 Avg: $96.38 Low: $87 Last Closed Price: $82.1

EW Stock Rating

Edwards Lifesciences stock's rating consensus is Buy, based on 48 Wall Street analysts. The breakdown includes 0 Strong Buy (0.00%), 32 Buy (66.67%), 16 Hold (33.33%), 0 Sell (0.00%), and 0 Strong Sell (0.00%).

Buy
Total 48 16 32 0 Strong Sell Sell Hold Buy Strong Buy

EW Price Target Upside V Benchmarks

TypeNameUpside
StockEdwards Lifesciences17.39%
SectorHealthcare Stocks 15.45%
IndustryMedical Device Stocks31.84%

Price Target Trends

1M3M12M
# Anlaysts-1239
Avg Price Target-$98.50$94.03
Last Closing Price$82.10$82.10$82.10
Upside/Downside-19.98%14.53%
Ratings Trends
DateStrong BuyBuyHoldSellStrong SellTotal
Mar, 2651612--33
Feb, 2651612--33
Jan, 2651513--33
Dec, 2541514--33
Nov, 2541415--33
Analyst Price Target Forecasts
DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Feb 11, 2026Richard NewitterTruist Financial$89.00$76.8515.81%8.40%
Feb 11, 2026David RomanGoldman Sachs$95.00$77.0523.30%15.71%
Feb 11, 2026Piper Sandler$100.00$77.0529.79%21.80%
Feb 04, 2026Danielle AntalffyUBS$94.00$81.6315.15%14.49%
Jan 20, 2026Stifel Nicolaus$110.00$84.3530.41%33.98%
Jan 20, 2026Piper Sandler$98.00$84.3516.18%19.37%
Jan 12, 2026Danielle AntalffyUBS$95.00$83.5813.66%15.71%
Jan 12, 2026Robert W. Baird$90.00$83.697.54%9.62%
Jan 12, 2026Barclays$104.00$85.1322.17%26.67%
Jan 09, 2026David RomanGoldman Sachs$108.00$84.5827.69%31.55%
Analyst Rating Forecasts
DateCompanyPrevious RatingNew RatingRating Change
Feb 11, 2026Goldman SachsBuyBuyhold
Feb 11, 2026Piper SandlerOverweightOverweighthold
Feb 04, 2026UBSNeutralNeutralhold
Jan 20, 2026Piper SandlerOverweightOverweighthold
Jan 12, 2026UBSNeutralNeutralhold
Jan 12, 2026BarclaysOverweightOverweighthold
Jan 09, 2026Cowen & Co.HoldBuyupgrade
Jan 09, 2026Goldman SachsBuyBuyhold
Jan 05, 2026Evercore ISIOutperformOutperformhold
Dec 11, 2025CitigroupBuyBuyhold

Financial Forecast

EPS Forecast

$1 $2 $3 $4 $5 $6 $7 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$2.41$2.46$2.31$6.98$1.84---
Avg Forecast$2.26$2.46$2.51$2.57$2.44$2.74$3.11$3.49
High Forecast$2.43$2.55$2.52$2.60$2.53$2.96$3.40$3.66
Low Forecast$2.14$2.40$2.48$2.42$2.42$2.41$2.82$3.44
Surprise %6.64%--7.97%171.60%-24.59%---

Revenue Forecast

$5B $6B $6B $7B $8B $9B Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$5.23B$5.38B$5.01B$5.44B$6.07B---
Avg Forecast$5.26B$5.37B$5.97B$5.80B$5.82B$6.40B$7.09B$7.77B
High Forecast$5.55B$5.52B$6.00B$5.86B$5.86B$6.43B$7.16B$8.07B
Low Forecast$5.03B$5.26B$5.94B$5.33B$5.79B$6.37B$7.02B$7.69B
Surprise %-0.51%0.25%-16.07%-6.14%4.18%---

Net Income Forecast

$1B $2B $2B $3B $4B $5B Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$1.50B$1.52B$1.40B$4.17B$1.07B---
Avg Forecast$1.39B$1.53B$1.40B$1.57B$1.51B$1.59B$1.89B$2.12B
High Forecast$1.67B$1.84B$1.68B$1.58B$1.54B$1.81B$2.07B$2.23B
Low Forecast$1.11B$1.22B$1.12B$1.47B$1.48B$1.47B$1.72B$2.09B
Surprise %8.09%-0.49%-166.36%-28.93%---

EW Forecast FAQ

Is Edwards Lifesciences stock a buy?

Edwards Lifesciences stock has a consensus rating of Buy, based on 48 Wall Street analysts. The rating breakdown includes 0 Strong Buy, 32 Buy, 16 Hold, 0 Sell, and 0 Strong Sell, reflecting a consensus that Edwards Lifesciences is a favorable investment for most analysts.

What is Edwards Lifesciences's price target?

Edwards Lifesciences's price target, set by 48 Wall Street analysts, averages $96.38 over the next 12 months. The price target range spans from $87 at the low end to $110 at the high end, suggesting a potential 17.39% change from the previous closing price of $82.1.

How does Edwards Lifesciences stock forecast compare to its benchmarks?

Edwards Lifesciences's stock forecast shows a 17.39% upside, outperforming the average forecast for the healthcare stocks sector (15.45%) and underperforming the medical device stocks industry (31.84%).

What is the breakdown of analyst ratings for Edwards Lifesciences over the past three months?

  • March 2026: 15.15% Strong Buy, 48.48% Buy, 36.36% Hold, 0% Sell, 0% Strong Sell.
  • February 2026: 15.15% Strong Buy, 48.48% Buy, 36.36% Hold, 0% Sell, 0% Strong Sell.
  • January 2026: 15.15% Strong Buy, 45.45% Buy, 39.39% Hold, 0% Sell, 0% Strong Sell.

What is Edwards Lifesciences’s EPS forecast?

Edwards Lifesciences's average annual EPS forecast for its fiscal year ending in December 2026 is $2.74, marking a 48.91% increase from the reported $1.84 in 2025. Estimates for the following years are $3.11 in 2027, and $3.49 in 2028.

What is Edwards Lifesciences’s revenue forecast?

Edwards Lifesciences's average annual revenue forecast for its fiscal year ending in December 2026 is $6.4B, reflecting a 5.47% increase from the reported $6.07B in 2025. The forecast for 2027 is $7.09B, and $7.77B for 2028.

What is Edwards Lifesciences’s net income forecast?

Edwards Lifesciences's net income forecast for the fiscal year ending in December 2026 stands at $1.59B, representing an 47.82% increase from the reported $1.07B in 2025. Projections indicate $1.89B in 2027, and $2.12B in 2028.